ClinicalTrials.gg
RecruitingNCT06345079STOPNETUpdated Nov 12, 2026

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

A Phase 2 interventional study of Cessation of somatostatin analogues and Continuation of somatostatin analogues in Neuroendocrine Tumors, sponsored by Australasian Gastro-Intestinal Trials Group. Recruiting at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Australasian Gastro-Intestinal Trials Group · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 12, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Neuroendocrine Tumors with a site in Australia — 7 open to participants now, 12 under way, 3 of them phase 3. Neuroendocrine Tumors · Australia.

Planned enrollment
12th of 18
78 · median 121
Started
2024
the only one that year
Phase 2
8 of 22
1 open now
Primary completion
2027-09
later than 6 of 11 live
Registered
20th of 22
by date
Lead sponsor
1 of 22
Australasian Gastro-Intestinal Trials Group

Among the 22 studies in Neuroendocrine Tumors with a site in Australia, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, reaches primary completion later than 6 of the 11 other live ones, and was the 20th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

7 of the 22 studies in Neuroendocrine Tumors with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neuroendocrine Tumors with a site in Australia, or all of them as a file.
02

Study summary

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Read the detailed description

Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.

STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.

The two primary objectives include

  1. To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.
  2. Feasibility as measured by:

    1. Recruitment rate and
    2. Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.

The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Advanced
  • Unresectable grade 1 or 2
  • mid, hind- gut or pancreatic neuroendocrine tumours
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
  2. Must have on triphasic CT/MRI as per 1.1.
  3. Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).

    • Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
  4. Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.

    In addition, for this study, non-functioning tumour is defined as:

    • Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.
    • Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.
    • For mid and hind gut (GI cohort) patients:

      • 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) \<3x .
      • No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
    • Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
  5. Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
  6. Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.
  7. PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).
  8. performance status 0-2.
  9. Written . Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.
  10. Adequate renal, hepatic and haematologic function as judged by the treating team.
  11. of at least 12 months.

Exclusion criteria

Exclusion Criteria:

  1. This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
  2. Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
  3. Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
  4. Any to PRRT, as per local institutional practice.
  5. Pregnancy. For female patients of and male patients with a female partner who is of childbearing potential, and counselling is required.
  6. Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
  7. Uncontrolled central nervous system . Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off for at least 2 weeks.
  8. Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
  9. Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
  10. Any concurrent or prior that, in the opinion of the treating team, may interfere with study assessments and endpoints.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Continue SSA

    Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

    Drug: Continuation of somatostatin analogues

  • Experimental
    Cease SSA

    Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.

    Drug: Cessation of somatostatin analogues

Interventions

  • DrugCessation of somatostatin analogues

    Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

    Also known as: SSA cessation

  • DrugContinuation of somatostatin analogues

    Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

    Also known as: SSA continuation

06

What researchers measure

Primary outcomes

  1. 20-month progression free survival rate after PRRT

    Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA.

    Time frame: 20 months

  2. Assess the barriers which would impede the feasibility of a subsequent phase 3 trial

    1. Proportion of participants that remained on the SSA cessation arm for the duration of the 20-month study follow up (patient acceptance of SSA cessation). 2. Rate of recruitment: ability to complete recruitment over the 24-month recruitment period

    Time frame: 20 months

Secondary outcomes

  1. Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales

    Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning.

    Time frame: 20 months

  2. Measure Quality of life using the EORTC QLQ-GINET21 scales

    Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms.

    Time frame: 20 months

  3. Cost-effectiveness of SSA therapy cessation

    Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively.

    Time frame: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.

  4. Psycho-oncological impacts of SSA therapy cessation: Decision Regret

    Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree)

    Time frame: 20 months

  5. Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression

    Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often)

    Time frame: 20 months

  6. Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict

    Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree)

    Time frame: 20 months

  7. Time to commencement of subsequent therapy

    Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies)

    Time frame: 20 months

  8. Overall survival

    Estimate the 20-month overall survival rate in patients who cease and who continue SSA.

    Time frame: 20 months

  9. Rates of SSA being recommenced over time

    Cumulative percentage of SSA recommencement over time.

    Time frame: 20 months

Other outcomes

  1. Exploratory analyses

    Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA.

    Time frame: 20 months

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 85 non-industry phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 83. This study's planned 35 months is below that.

Counting every sponsor, half of 98 studies reached it within 65 months; a quarter within 42 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Apr 3, 2024
StartActual
Oct 14, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Jun 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
9 inclusion criteria edited, 3 added, 1 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAdults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour,; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
  • EditedKi67 ≤ 20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).
  • AddedNote: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
  • EditedNon-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology. In addition, for this study, non-functioning tumour is defined as:
  • AddedIn addition, for this study, non-functioning tumour is defined as:
  • EditedNever had escalation of the SSA treatment dose to control carcinoid carcinoid or other hormone-related symptoms.
  • EditedNever required short acting SSA treatment to control carcinoid carcinoid or other hormone-related symptoms.
  • AddedFor mid and hind gut (GI cohort) patients:
  • Edited24-hour urine 5-hydroxyindoleacetic acid (5HIAA) of <1.5x3x upper limit of normal (applies to mid and hind gut patients only).
  • EditedNo significant carcinoid induced valvular heart disease IE:. I.e. Echocardiogram to be done in all patients within 2612 weeks of study enrolmentrandomisation, and deemed safe to proceed with PRRT by the treating team.
  • EditedPlease noteNote: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
  • EditedPatient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study entry. This isenrolment, for example a minimum of 30 mg30mg Octreotide or120mg lanreotideor 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
  • RemovedAvailability of tissue from resection or biopsy samples is desired but is not mandatory for study inclusion. Tissues will only be retrieved if the patient consents to optional translational research sample collection. Similarly, bloods for research purposes will only be collected from those patients who consent to optional translational research sample collection.
Exclusion criteria
  • EditedAny patient on an SSA dose lower than the standard growth-control dose. Patients must have been on octreotide 30 mgan SSA equivalent to Octreotide 30mg or lanreotide 120 mgLanreotide 120mg for at least 3 months prior to study entryenrolment.
  • EditedUncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to registrationenrolment and must be off corticosteroids for at least 2 weeks.
Nov 12, 2026
Contact
Study contact changed: g•••@gicancer.org.au · •••2725→g•••@gicancer.org.au · •••6769. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Eligibility 9 inclusion criteria edited, 3 added, 1 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour,; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).
    • EditedKi67 ≤ 20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).
    • AddedNote: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.
    • EditedNon-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology. In addition, for this study, non-functioning tumour is defined as:
    • AddedIn addition, for this study, non-functioning tumour is defined as:
    • EditedNever had escalation of the SSA treatment dose to control carcinoid carcinoid or other hormone-related symptoms.
    • EditedNever required short acting SSA treatment to control carcinoid carcinoid or other hormone-related symptoms.
    • AddedFor mid and hind gut (GI cohort) patients:
    • Edited24-hour urine 5-hydroxyindoleacetic acid (5HIAA) of <1.5x3x upper limit of normal (applies to mid and hind gut patients only).
    • EditedNo significant carcinoid induced valvular heart disease IE:. I.e. Echocardiogram to be done in all patients within 2612 weeks of study enrolmentrandomisation, and deemed safe to proceed with PRRT by the treating team.
    • EditedPlease noteNote: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.
    • EditedPatient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study entry. This isenrolment, for example a minimum of 30 mg30mg Octreotide or120mg lanreotideor 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.
    • RemovedAvailability of tissue from resection or biopsy samples is desired but is not mandatory for study inclusion. Tissues will only be retrieved if the patient consents to optional translational research sample collection. Similarly, bloods for research purposes will only be collected from those patients who consent to optional translational research sample collection.
    Exclusion criteria
    • EditedAny patient on an SSA dose lower than the standard growth-control dose. Patients must have been on octreotide 30 mgan SSA equivalent to Octreotide 30mg or lanreotide 120 mgLanreotide 120mg for at least 3 months prior to study entryenrolment.
    • EditedUncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to registrationenrolment and must be off corticosteroids for at least 2 weeks.
    Contact Study contact changed: g•••@gicancer.org.au · •••2725→g•••@gicancer.org.au · •••6769. See the current contact
    + 3 other changes: verification date, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06345079
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Collaborators
Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Oct 14, 2024
Primary completion
Sep 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

STOPNET Project Manager
Contact
gct_stopnet_mailbox@gicancer.org.au
+61 1300 666 769

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion